A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor (ACHIEVE-5)
Phase 1
Recruiting
- Conditions
- Type 2 DiabetesTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Registration Number
- CTIS2023-507280-18-00
- Lead Sponsor
- Eli Lilly & Co.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 520
Inclusion Criteria
Have Type 2 Diabetes (T2D), Be taking a consistent dose of diabetes drug by injection for at least 3 months., May be taking up to 2 diabetes drugs by mouth for at least 3 months., Have a high blood sugar.
Exclusion Criteria
Have Type 1 diabetes., Have history of an inflamed pancreas (pancreatitis)., Have history of an inflamed liver (hepatitis)., Have congestive heart failure.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method